• 1
    Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. PharmacoEconomics 1994; 6: 51322.
  • 2
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 134653.
  • 3
    Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982; 9: 78993.
  • 4
    Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38: 156880.
  • 5
    Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long term followup data and the effect on quality of life. Scand J Rheumatol 1992; 21: 2933.
  • 6
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 7
    Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81: 56578.
  • 8
    Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Bennett KJ, et al. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 5962.
  • 9
    Ware JE, Sherbourne CD. The MOS SF-36 item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 10
    Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcon G, et al. Cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. J Rheumatol 1997; 24: 19105.
  • 11
    Talamo J, Frater A, Gallivan S, Young A. Use of the Short Form 36 for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997; 36: 4639.
  • 12
    Ruta DA, Hurst JP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 42536.
  • 13
    Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Suarez-Almazor M, et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis. J Rheumatol. In press.
  • 14
    Silva HT, Morris RE. Leflunomide and the malanonitriloamides. Am J Med Sci 1997; 313: 289301.
  • 15
    Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595603.
  • 16
    Schiff M, Kaine J, for the Leflunomide RA Investigators Group, Sharp J, Strand V. X-ray analysis of 12 months treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S155.
  • 17
    Smolen JS, Kalden JR, Scott DL, and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 1999; 353: 25966.
  • 18
    Hoechst Marion Roussel, Inc. Leflunomide [package insert]. Kansas City (MO): Hoechst Marion Roussel, Inc; 1998.
  • 19
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon GW, et al, on behalf of the Leflunomide RA Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Archives Int Med. In press.
  • 20
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 21
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health status survey manual. Boston: The Health Institute, New England Medical Center; 1993.
  • 22
    Tomlin GS, Holm MB, Rogers JC, Kwoh CK. Comparison of standard and alternative health assessment questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 152430.
  • 23
    Goldsmith C, Boers M, Bombardier C, Tugwell P, for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol 1993; 20: 5615.
  • 24
    Wells G, Tugwell P, Kraag G, Baker P, Groh J, Redelmeier D. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 25
    Guzman J, Maetzel A, Peloso P, Yeung M, Bombardier C. Disability scores in DMARD trials: what is a clinically important change? [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S208.
  • 26
    Fries JF, Williams CA, Ramey DR, Singh G. Medical costs are strongly associated with disability levels in rheumatoid arthritis [abstract]. Arthritis Rheum 1995; 38 Suppl 9: S187.
  • 27
    Singh G, Terry R, Ramey D, Wolfe F, Fries J. Long-term medical costs and outcomes are significantly associated with early changes in disability in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S318.
  • 28
    Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, et al. The SF-36 is sensitive to changes in quality of life in SLE patients [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S225.